Synergistic beeswax-based nano-formulation for enhanced chronic wound healing and antibacterial potency - PubMed
3 days ago
- #antibacterial potency
- #chronic wound healing
- #beeswax nano-formulation
- Novel beeswax-encapsulated nano-formulation (F4) developed for chronic wound healing and antibacterial potency.
- F4 combines delafloxacin (DLX), lidocaine (LIDO), and sodium hyaluronate (SHA) with high encapsulation efficiency (87.6-91.3%).
- Optimal nanoparticle characteristics: size 115.68 nm, PDI 0.26, zeta potential -31.70 mV.
- pH-responsive sustained release (94-100% at 24 h, pH 7.4) with diffusion-controlled mechanism.
- Enhanced antibacterial activity: larger inhibition zones, 4-fold lower MICs against S. aureus and E. coli.
- Disrupts biofilms at sub-MIC levels and achieves complete bactericidal killing of S. aureus within 12 h.
- High biocompatibility (CC50: 872.40 µg mL-1) with >80% fibroblast viability at therapeutic doses.
- Addresses infection control, analgesia, tissue regeneration, and controlled delivery for chronic wounds.